Sudden Lapse of Vision Could Be a Sign of Stroke: TCM Diet May Clear Your Blood Vessels
Transient Amaurosis: An Indication of Cerebrovascular Issues
If you've ever experienced a sudden blackout in front of your eyes, were unable to see, and then quickly returned to normal, you've experienced transient amaurosis.
Chen Huixuan, director of the Department of Neurology at Chang'an Hospital in Taiwan, stated on the NTDTV program 'Health 1+1' that transient amaurosis is like the eyes being covered by a black cloth from above, like a curtain that suddenly drops. In most cases, one eye will see darkness or even turn completely blind, and then automatically return to normal within seconds to minutes. It is a temporary and painless loss of vision.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts
Inspire Medical Systems, Inc. INSP delivered an earnings per share (EPS) of 45 cents in second-quarter 2025, up 40.6% year over year. The figure topped the Zacks Consensus Estimate by 104.6%. INSP's Revenues in Detail Inspire Medical registered revenues of $217.1 million in the second quarter, up 10.8% year over year. The figure beat the Zacks Consensus Estimate by 0.9%. Per management, the overall revenue growth was primarily driven by increased market penetration and increased physician and patient awareness of the Inspire system. However, this was partially offset by ENT surgeon capacity constraints and some U.S. patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications. Shares of this company lost nearly 24.9% in today's pre-market trading. Inspire Medical's Segment Details Inspire Medical's operations consist of two geographic regions — the United States and All other countries. In the quarter under review, U.S. revenues of $207.2 million reflected an increase of 10.3% from the year-ago quarter on a reported basis. As of June 30, 2025, Inspire Medical had 348 U.S. sales territories and 259 field clinical representatives compared with 335 and 230, respectively, as of Dec. 31, 2024. Revenues from All other countries totaled $9.9 million, up 23% year over year on a reported basis. Inspire Medical Systems, Inc. Price, Consensus and EPS Surprise Inspire Medical Systems, Inc. price-consensus-eps-surprise-chart | Inspire Medical Systems, Inc. Quote INSP's Margin Analysis In the second quarter, Inspire Medical's gross profit increased 9.9% year over year to $182.4 million. However, the gross margin contracted 74 basis points (bps) to 84%. Selling, general and administrative expenses jumped 20.8% year over year to $159.5 million. Research and development expenses decreased 9.2% year over year to $26.2 million. Operating expenses of $185.7 million increased 15.4% year over year. Operating loss totaled $3.3 million against the prior-year quarter's operating profit of $5.1 million. Inspire Medical's Financial Position Inspire Medical exited second-quarter 2025 with cash and cash equivalents and short-term investments of $300.9 million compared with $369.2 million at the first-quarter end. Cumulative net cash used in operating activities at the end of second-quarter 2025 was $4 million, against net cash provided by operating activities of $8.8 million a year ago. INSP's Outlook Inspire Medical has lowered its revenue and EPS outlook for 2025. The company now projects revenues in the range of $900 million-$910 million (representing growth of 12-13% from 2024 levels), lowered from the prior outlook of $940 million-$955 million (representing growth of 17-19% from 2024 levels). The Zacks Consensus Estimate is pegged at $949.1 million. The company now expects its EPS for 2025 to be between 40 cents and 50 cents, lowered from the prior outlook of $2.20-$2.30. The Zacks Consensus Estimate is pegged at $2.26. Our Take on Inspire Medical Inspire Medical exited the second quarter of 2025 with better-than-expected results. The robust improvement of the top and bottom lines was impressive. Strength in year-over-year geographical revenues was promising. The increased market penetration and increased physician and patient awareness of the Inspire system during the reported quarter were encouraging. However, the gross margin contracted due to rising product costs. This does not bode well for the stock. Also, management's confirmation about the slower-than-expected progress of the U.S. commercial launch of Inspire V is worrying. Per management, this has resulted in the pushing forward of the timeline to complete the full transition to Inspire V, which will impact financial results for the year. INSP's Zacks Rank and Key Picks Inspire Medical currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Journals
3 hours ago
- Business Journals
UPMC Hillman is an NCI-designated Comprehensive Cancer Center: What this means for patients
A cancer diagnosis changes someone's life—and so can the cancer center they choose for treatment. UPMC Hillman Cancer Center is western Pennsylvania's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, a distinction held by just 57 centers around the country. The NCI is our nation's leading cancer authority, and its Comprehensive Cancer Center program recognizes centers that are conducting groundbreaking research to develop new and better ways to prevent, diagnose, and treat cancer. For patients, treatment at an NCI-designated Comprehensive Cancer Center can mean better outcomes, according to a 2015 study of individuals with newly diagnosed adult-onset cancer. 'The advances that have been made of the past 10-plus years have really changed the landscape of cancer care,' says Stanley M. Marks, MD, UPMC Hillman's chairman. 'We can successfully treat difficult cancers now that 10 or 15 years ago, we never dreamt that we could. But in addition to better outcomes, the quality of life has improved.' NCI designation is earned, not paid for or determined by peer nomination. Centers must demonstrate excellence in research across multiple branches of science and among a multidisciplinary team. Every five to seven years, UPMC Hillman undergoes a rigorous evaluation—including an extensive grant application and assessments of its research activities—to maintain its status. expand From Bench to Bedside More than 300 UPMC Hillman scientists work together to investigate all aspects of cancer, from how it develops and behaves at the molecular level to how genetic, environmental, and lifestyle factors influence someone's cancer likelihood. The team engages in bench-to-bedside practices, working collaboratively with physicians to translate promising laboratory findings into new and better therapies, diagnostic tools, and prevention strategies. UPMC Hillman experts have made groundbreaking discoveries and pioneered new treatments to improve patient care, including: Discovering two of the seven known cancer-causing viruses Being the first to use natural killer cells, a type of immune cell, against cancer Demonstrating that changing the gut microbiome through fecal transplant can enable patients with melanoma who did not previously respond to immunotherapy to successfully respond Being the first to use a synthetic vaccine called MUC-1 against cancer Creating national guidelines for exercise as a means to reduce the severity of chemotherapy symptoms Developing the first vaccine targeting ductal carcinoma in situ, a type of pre-invasive breast cancer Nationally Recognized Care in Local Communities UPMC Hillman's NCI designation extends throughout its entire network, which includes nearly 80 locations in communities throughout Pennsylvania, Ohio, New York, and Maryland, well beyond its flagship facility in Pittsburgh. This means that patients can receive the latest evidence-based care and ongoing support with little or no need to travel. 'We strive for all our locations to deliver the same care the patients would receive if they came to Pittsburgh,' Dr. Marks says. 'For the most part, 90% of cancer care can be delivered in the community, and we want patients to be treated closer to home.' At UPMC Hillman Cancer Center, we understand the complexity of cancer. Learn more about our research and clinical trials here. UPMC Hillman Cancer Center is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is harnessing the expertise of physicians, scientists and allied health care professionals who deliver comprehensive clinical care, lead cutting-edge research, train future generations of cancer experts and engage with our communities to detect, treat and prevent cancer.
The Hill
4 hours ago
- The Hill
Former X CEO Linda Yaccarino has a new job
Former X CEO Linda Yaccarino said Tuesday that she has taken on a new role leading a digital health platform, less than a month after announcing her departure from Elon Musk's social media platform. Yaccarino is joining eMed Population Health, which provides support for patients on GLP-1 medications, as CEO. 'Our mission is revolutionizing how people receive safe, effective care for chronic condition management through GLP-1 therapies, while building the programs and technologies needed to sustain lasting health outcomes,' she wrote in a post on X. 'This is truly a transformational moment in preventative healthcare, and I'm energized by the opportunity to help lead what could become the most impactful health initiative of our time,' she continued. Yaccarino spent two years as CEO of X following Musk's acquisition of the platform then known as Twitter in 2022. She joined the company about six months after the tech mogul's takeover, leaving her role at NBCUniversal Media as chair of global advertising and partnerships. Her tenure at the social media platform was marked by upheaval and crises, as Musk repeatedly alienated advertisers and made numerous controversial changes, including rebranding the site as X. She announced her plans to leave the company in early July, saying she was 'immensely grateful to [Musk] for entrusting me with the responsibility of protecting free speech, turning the company around, and transforming X into the Everything App.'
